NeuroBionics Secures an Oversubscribed $5M Seed Round to Advance Endovascular Neuromodulation Technology
NeuroBionics, a neurotech company revolutionizing neuromodulation therapy with minimally invasive implantable devices, today announced the successful close of its $5 million Seed Round. The round was led by Dolby Family Ventures with Future Ventures, GreyMatter Capital, Focalpoint Partners, Lionheart Ventures, Jumpspace Ventures, and Dr. Thomas Insel, former Director of the National Institute of Mental Health. The funding will enable NeuroBionics to accelerate the development of its cutting-edge endovascular neuromodulation platform. Building upon over a decade of innovation at the Massachusetts Institute of Technology, NeuroBionics aims to expand access to neuromodulation therapies for millions of patients with neurological disorders through a minimally invasive approach to neuromodulation.
